Abstract 5P
Background
Axillary lymph node metastases from adenocarcinoma or poorly differentiated carcinoma of unknown primary (CUPAx) is a rare disease in women. This subgroup shares similar biological characteristics with stage II-III breast cancer and is named occult breast cancer (OBC). This study intended to examine the clinicopathological features of OBC and compared OBC genetically with axillary lymph node metastases from breast cancer (BCAx), investigating differences in their biological behavior.
Methods
We conducted the clinical and prognostic analysis of 58 OBC patients in West China Hospital spanning from 2009 to 2021. Gemonic profiling of 12 OBC patients and 16 BCAx patients was conducted by the FoundationOne CDx (F1CDx) platform, including 324 genes along with genomic features such as TMB and MSI. Moreover, we also compared the gene mutation spectrum and relevant pathways between the two groups and both TCGA and COSMIC databases.
Results
The majority of the 58 OBC patients were HR-/HER2- subtype. OBC patients had a higher expression of breast origin-related immunohistochemical markers, such as GATA3, GCDFP15, and CK5/6. Most patients received mastectomy combined radiotherapy (50Gy/25f). OBC had a favorable overall prognosis. Radiotherapy was the independent prognostic factor in multivariate analysis (HR=0.04, 95%CI=0.00-0.85, P=0.0390). In 28 samples and 401 TCGA-BRCA patients, IRS2 only mutated in OBC (33.33%) but amplified in BCAx (11.11%) and TCGA-BRCA (1.5%). Pathway analysis revealed that BCAx had more NOTCH pathway mutations than OBC, where NOTCH3 and GATA3 was highly amplified in OBC (16.67% vs. 0%) and BCAx (16.67% vs. 0%) respectively. GATA6 only had novel mutations in BCAx (31.25%) according to the COSMIC database. Enrichment analysis showed that OBC enriched more in mammary development and PML bodies than BCAx, but less in the positive regulation of kinase activity.
Conclusions
More active treatment methods could improve the prognosis of OBC. The differential mutation genes of OBC and BCAx might be associated with their respective biological behaviors like invasiveness and prognosis. The differences in NOTCH pathway and enrichment analysis might cause the occult lesions in the OBC.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
1.3.5 Project for Disciplines of Excellence, West China Hospital, Sichuan University (ZYJC18022 and ZYJC21017).
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
102P - Enhancing colorectal cancer prevention in high-risk populations through faecal immunochemical test surveillance
Presenter: Li Xie
Session: Poster Display
Resources:
Abstract
103P - Anlotinib plus chemotherapy as first-line therapy for gastrointestinal tumor patients with unresectable liver metastasis: Updated results from a multi-cohort, multi-center phase II trial ALTER-G-001-cohort A
Presenter: Junwei Wu
Session: Poster Display
Resources:
Abstract
104P - The value of functional MR-imaging signature model for early prediction of chemotherapy response and its guidance for regimen adjustment to improve efficacy
Presenter: Wenhua Li
Session: Poster Display
Resources:
Abstract
105P - A single-arm, phase II, multicenter study of iparomlimab (QL1604) in patients (pts) with unresectable/metastatic deficient mismatch repair (dMMR)/microsatellite instability high (MSI-H) solid tumors
Presenter: Weijian Guo
Session: Poster Display
Resources:
Abstract
106P - Efficacy and safety of IBI351 (GFH925) monotherapy in metastatic colorectal cancer harboring KRASG12C mutation: Updated results from a pooled analysis of two phase I studies
Presenter: Ying Yuan
Session: Poster Display
Resources:
Abstract
107P - Tumor-stromal ratio in a new age fibroblast activated protein PET imaging as a biomarker for prediction of response to neoadjuvant chemoradiotherapy in carcinoma rectum
Presenter: swetha Suresh
Session: Poster Display
Resources:
Abstract
108P - Detection of HER2 overexpression in colorectal cancer: Comparison of a HANDLE classic NGS panel with standard IHC/FISH
Presenter: Lijuan Luan
Session: Poster Display
Resources:
Abstract
109P - Early onset metastatic colorectal cancer: Clinical-prognostic characteristics and correlation to molecular status
Presenter: Andrea Pretta
Session: Poster Display
Resources:
Abstract
110P - The correlation between multi-dimensional characteristics of circulating tumor cells (CTC) and treatment response in patients with initially unresectable metastatic colorectal cancer
Presenter: Yu Liu
Session: Poster Display
Resources:
Abstract
111P - Comparison of the efficacy and safety of fruquintinib and fruquintinib combined with immune checkpoint inhibitors in the treatment of metastatic microsatellite stable colorectal cancer: A real-world study
Presenter: Zhiqiang Wang
Session: Poster Display
Resources:
Abstract